AstraZeneca PLC (AZN)vsHinge Health, Inc. (HNGE)
AZN
AstraZeneca PLC
$172.48
+0.48%
HEALTHCARE · Cap: $261.94B
HNGE
Hinge Health, Inc.
$74.09
-1.58%
HEALTHCARE · Cap: $6.79B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 9251% more annual revenue ($60.44B vs $646.34M). AZN leads profitability with a 17.2% profit margin vs -78.9%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
HNGE
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+10.7%
Fair Value
$193.96
Current Price
$172.48
$21.48 discount
Intrinsic value data unavailable for HNGE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 27.9%
Generating 2.1B in free cash flow
Revenue surging 47.2% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Weak financial health signals
Trading at 51.1x book value
ROE of -197.2% — below average capital efficiency
Earnings declined 68.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : HNGE
The strongest argument for HNGE centers on Revenue Growth, Debt/Equity. Revenue growth of 47.2% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : HNGE
The primary concerns for HNGE are Piotroski F-Score, Price/Book, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while HNGE is a hypergrowth play — different risk/reward profiles.
HNGE is growing revenue faster at 47.2% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (64/100 vs 34/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Hinge Health, Inc.
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Hinge Health, Inc. develops health care software for joint and muscle health. The company is headquartered in San Francisco, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?